PureTech's Gelesis scraps plans for a $60M IPO

A flood of IPOs can't raise every biotech boat. Gelesis has scrapped its plans for a $60 million IPO after evidently failing to find a big enough appetite for its stomach-filling particle approach to combating obesity. The biotech, part of PureTech's portfolio, is shooting to wrap a pivotal study in Europe but noted in its S-1 that it could take four more years to prep for a U.S. approval. The biotech--which raised a $22 million crossover round a couple of months ago--had a problem with its most recent study, which was completed last summer. The study tested Gelesis100 at a 2.25 g dose, a 3.75 g dose and a placebo. That low dose scored a placebo-adjusted weight loss of only 2% of body weight (6.1% total), while the high dose registered a minimal 0.4% placebo-adjusted improvement on the scales. Story

Suggested Articles

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.